Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. Zhao Y, Zhang L, Wu L, Yang B, et al. Allergy 2024 Oct 25. doi: 10.1111/all.16368.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao Y, Zhang L, Wu L, Yang B, et al. Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial. Allergy 2024 Oct 25. doi: 10.1111/all.16368.
PMID: 39450683